Clinical trials based on the Stroke Riskometer

Welcome to the Stroke Riskometer app and the RIBURST study.

On this page, you can:

  1. Join the RIBURST study as a scientific collaborator
  2. Request permission to use the Stroke Riskometer for your study
  3. Register your study based on the Stroke Riskometer
  4. Find a past or current study that is using the Stroke Riskometer
  5. App-related resources
  6. Contact us

NOTE: If you use the Stroke Riskometer data or app in your research you must acknowledge this in any relevant publications or presentations. Please use the following wording: “We acknowledge the use of Stroke Riskometer data /the Stroke Riskometer app in this study. The Stroke Riskometer app was developed by and is copyrighted by Auckland University of Technology, Auckland, New Zealand”.

Find a past or current study that is using the Stroke Riskometer

Find out which other studies have been or are being carried out based on the Stroke Riskometer app. For more information, contact the lead investigator.


  • Project: Health message appeal and Facebook audience engagement: Evidence from the Stroke Riskometer application
  • Start date: 2022
  • End date: 2022
  • Lead investigator: Dr Ekaterina Volevach, International Clinical Research Centre, St Anne University Hospital,     Brno, Czech Republic.
  • Abstract: This is an exploratory quasi-randomized study to determine efficacy of three types of message appeals (positive, negative, rational) in the area of stroke prevention (using the free Stroke Riskometer app) on audience engagement. The comparison between message appeals will be done using the split test on Facebook users with increased risk of stroke. The study population will be defined through a special audience creator in Facebook Ad manager and the inclusion criteria for the study are: location in the Czech Republic, 20+ years old, excessive alcohol consumption or smoking, poor diet, lack of adequate physical activity.


  • Project: Pragmatic, factorial, cluster randomised controlled trial on primary stroke prevention in Brazil
  • Start date: 2021
  • End date: 2021
  • Lead Investigator: President of Brazilian Stroke Network, Neurology Professor of Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. E=
  • Abstract: The project aims to measure the engagement of the Stroke Riskometer app.  It will also test the feasibility of the PreventS webapp, which is built on the stroke Riskometer app.


  • Project: PERsonalised Knowledge to reduce the risk of Stroke (PERKS-International)
  • Start date: 2021
  • End date: 2024
  • Lead Investigator: Associate Professor Seana Gall - Menzies Institute for Medical Research, University of Tasmania. Menzies Institute for Medical Research, University of Tasmania, Hobart 7005, Australia. T =+61 3 6226 4728 E=
  • Abstract: This is a Phase III, prospective, pragmatic, open-label, single blinded endpoint 2 arm randomised controlled trial (RCT) including 790 participants across Australia and New Zealand. Participants will be adults aged >35 and ≤75 years with two or more modifiable risk factors (smoking, overweight, low physical activity, poor diet, high blood pressure, high total cholesterol or high blood glucose) measured using the Life's Simple 7 (LS7) index. Participants will be randomised using a stratified block approach to either the intervention or usual care group. Participants in the intervention group will be provided with the Stroke Riskometer App whereas those in the usual care group will not be informed about the Stroke Riskometer App. Blinded assessments will be conducted face-to-face at baseline and 6 months and by online or telephone assessment at 3 and 12 months. The primary outcome is a 0.4 point increase in the total LS7 score from baseline to 6 months post-randomisation in the intervention compared to usual care group.


  • Project: Reducing the International Burden of Stroke Using Mobile Technology): The Stroke Riskometer research project (RIBURST)
  • Start date: 2014
  • Lead Investigator: Professor Valery Feigin, National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, New Zealand.
  • Abstract: RIBURST is an international collaborative study that aims to better understand the risk factors associated with stroke, heart attack, dementia and diabetes mellitus and to assess how much influence each risk factor has on the likelihood of having a stroke, heart attack, dementia and diabetes mellitus in the future. The Stroke Riskometer app already involves over 300 renowned stroke experts from 102 countries making it the largest  international -collaborative mobile health project in the world.



  • Project: Trial of an Individualised Intervention for the Prevention of Stroke (TIIPS)
  • Start date: 2022
  • End date: 2024
  • Lead Investigator: Professor Valery Feigin, National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, New Zealand.
  • Study manager: Dr Sulekha De Silva, Auckland University of Technology, New Zealand. NISAN, AUT University, Private Bag 92006, Auckland 1142, New Zealand.
  • Abstract: TIA and minor stroke are at high risk of secondary vascular events including major stroke, myocardial infarction, cognitive deficits and death, as high as 25% within 90 days. Evidence suggests modifying health behaviours prevention is feasible, improves health outcomes, reduces healthcare costs, risk of stroke by about 80%, and stroke incidence about 50%. Health behaviours, lifestyle interventions, can lead to reductions in CVD and stroke. Health and wellness coaching (HWC) is a multidimensional intervention improving lifestyle and maintaining health and wellbeing. The main aim is to determine the effectiveness of HWC in improving blood pressure at 6 months post-randomisation and secondary aimsare to determine the impact of HWC on overall cardiovascular disease risk based on the LS7, use of the Stroke Riskometer app; quality of life; stroke awareness; cognition; medication adherence, adverse cardiovascular events, health service use and costs. Detect at least a 6 mm Hg clinically significant difference in systolic BP changes at 6 months from baseline, between the HWC and UC groups. Following screening for eligibility, consenting and the baseline assessment, participants will be randomised to Usual Care for HWC groups. Assessments are conducted at 3-, 6-, 9- and 12- months post-randomisation. The trial will determine HWC will lead to clinically meaningful improvements in lifestyle behaviours and reduce the risk for secondary vascular events including major stroke.


  • Project: Influence of Stroke Riskometer Application (SRA©) on lifestyle changes: A pilot randomised controlled trial among Malaysian caregivers
  • Start date: December 2018
  • End date: May 2019
  • Lead investigators: Dr Aznida Firzah Abdul Aziz, Dr Radhiyah Hussin, UKM Medical Center, Jalan Yaacob Latiff, 56000 Bandar Tun Razak, Kuala Lumpur
  • Abstract: The burden of caregiving plus the familial stroke risk factor(s) predisposes caregivers to stroke. User-friendly health-related applications could empower caregivers to recognize their risk for stroke. This study aimed to assess the impact of primary prevention delivery via a smartphone application to influence stroke caregivers toward healthier lifestyle. A parallel, open-label, 2-arm prospective, pilot randomized controlled trial was conducted at a long-term stroke service of UKMMC Primary Care Clinic from December 2018 until May 2019. All stroke caregivers >=18 years, able to operate a smartphone and literate in either English or Malay were recruited. Calculation of stroke risk and profiling of current lifestyle practices was done using Stroke Riskometer© application (SRA) and Life’s Simple 7 (LS7) questionnaires respectively. Seventy-five participants (38 SRA, 37 conventional care) were recruited from 147 eligible caregivers.Both groups of patients received standard health counselling prior to randomisation. The intervention group (n=38) had additional SRA installed on their smartphones , which enabled self-monitoring of stroke risk. The mean age of caregivers in both groups differed slightly (46.0 ±1.3 years vs 45.6±12.8, p=0.87). The majority of participants were female, Malay and educated up to secondary level. The stroke risk at 5- and 10-years in both groups were reduced after 3 months (5-,10-years: SRA 24.5%, 7.1%; Conventional care: 16.7%, 6.7%) as well as relative risk for stroke at 5-and 10 years (5-years: 16.5%, 9.3%; 10-years:15.0%,18.4%). LS7 scores improvement within groups: SRA-53.9% vs 33.3% (p=0.021). Usage of SRA and LS7 may benefit promotion of healthy lifestyle practices.


  • Project: The feasibility and efficacy of the Stroke Riskometer™ Pro App in improving lifestyle factors and reducing stroke risk among patients with type 2 diabetes mellitus in Malaysia: A pilot study
  • Start date: July 2018
  • End date: July 2019
  • Lead investigators: Dr Wan Asyraf Wan Zaidi, Tee Meng Kang and Prof Norlinah Mohamed Ibrahim, UKM Medical Center, Jalan Yaacob Latiff, 56000 Bandar Tun Razak, Kuala Lumpur
  • Abstract: The study determined the feasibility and efficacy of SR in improving blood pressure, body mass index [BMI]), modified Life’s Simple 7 score, fasting blood glucose, fasting lipids and HbA1c among patients with type 2 diabetes mellitus (T2DM). Forty-six T2DM patients, aged of ≥20 years were non-randomly recruited into Riskometer group (RG) (n=23) and usual care group (UCG) (n=23). The RG participants were asked to download SR into their smartphone, and were required to use it regularly. The UCG study participants did not have a smartphone and received usual medical care. All outcome parameters were measured at baseline and 3 months. Results: The use ofSR in patients with T2DM is well accepted and feasible. The mean total mLS7 score improved significantly in RG compared to UCG (6.65±1.55 vs 5.43 ± 1.27), p=0.006, mean difference of 1.217). The blood pressure (BP), exercise sub-scores of mLS7, and the mean diastolic blood pressure improved significantly in RG compared to controls (0.96± 0.56 vs 0.52 ±0.59, p=0.014; 1.09±0.60 vs 0.35±0.49, p<0.001; 74mmHg vs 81mmHg, p=0.004, respectively). The 5- and 10-year stroke risks improved significantly from baseline to 3 months in RG: 4.98% to 4.75%, p=0.001; and 12.48% to 11.93%, p=0.001, respectively.Conclusion: SR is feasible and potentially effective in controlling BP, level of physical activity, cardiovascular health, and 5- and 10-year stroke risks in T2DM patients.


  • Project: Validation of the Bahasa Malaysia Version of the Stroke RiskometerTM – A Tool for stroke primary prevention
  • Start date: 2017
  • End date: 2018
  • Lead investigators: Dr Wan Asyraf Wan Zaidi, Prof Norlinah Mohamed Ibrahim, UKM Medical Center, Jalan Yaacob Latiff, 56000 Bandar Tun Razak,Kuala Lumpur
  • Abstract: This study aimed to validate the Malay version of Stroke RiskometerTM among Malay speaking subjects. Both English and Bahasa Malaysia (BM) versions of Stroke RiskometerTM were administered to the respondents at the UKM Medical Center. The validity and reliability of the 5 and 10-year risk were determined using intraclass correlation and Cronbach’s Alpha analysis. A total of 200 participants were recruited with a mean age of 39.26 ± 14.09 years. There were 54% males and 46% females. The majority was of Malay ethnicity (78%) followed by Chinese (15%), Indian (5%) and others (2%). A total of 58.5% preferred the BM-Stroke RiskometerTM.  The outcome of the test-retest reliability study showed that agreement between English-Stroke RiskometerTM and BM-Stroke RiskometerTM was strong for both 5 and 10-year stroke risk with intraclass correlation (ICC) of 0.979 (95% CI, 0.972 – 0.984) for 5-year risk and 0.983 (95% CI, 0.978 – 0.987) for 10-year risk. The Cronbach’s Alpha were 0.989 and 0.991 respectively. Conclusion: The BM-Stroke RiskometerTM is a valid and reliable tool to measure the risk of stroke in 5 and 10-year times, comparable with English-Stroke RiskometerTM version.


  • Project: Mobile Application to Reduce Risk of Stroke (MARS)
  • Start date: 2016
  • End date: 2019
  • Lead investigator: Professor Valery Feigin, Auckland University of Technology, New Zealand. NISAN, AUT University, Private Bag 92006, Auckland 1142, New Zealand.
  • Abstract: The MARS trial was a pragmatic pilot, open-label, 2-arm prospective RCT. Consented participants were randomly assigned to the intervention arm using online minimization randomization. Usual care participants were not actively informed about the App. Changes in lifestyle behavior were measured at baseline, 3- and 6-months and assessed using Life’s Simple 7 (LS7) questionnaire as recommended by the American Heart Association. Questions about stroke symptoms and risk factors were asked to measure awareness levels. Positive feedback was received from study participants for the App as a tool to know more about stroke and take action for better health. Conclusions: The findings suggest the Stroke Riskometer is a feasible intervention for stroke awareness and prevention, and the results indicated that a full scale RCT to test the effectiveness of the app was warranted.
  • Related publications: Krishnamurthi, R., Bhattacharjee, R., George, A., Parmar, P., Barker-Collo, S., & Feigin, V. (2018). Using a mobile app to improve stroke awareness and reduce the risk of stroke - the pilot randomised control MARS trial [poster]. In 11th World Stroke Congress. Montreal, Canada.

Contact us

For information about the app or the RIBURST study, contact the project manager at